Published Manuscripts (2016)

Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS ONE 2016; 11(11): e0160421.

Smith-Palmer J, Bae JP, Boye KS, Norrbacka K, Hunt B, Valentine W. Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. ClinicoEconomics and Outcomes Research 2016; 8: 559-571.

Bruhn D, Martin AA, Tavares R, Hunt B, Pollock RF. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics 2016; 19(7): 672-83.

Muduma G, Odeyemi I, Pollock RF. A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK. Journal of Medical Economics 2016; 19(10): 995-1002.

Roze S, Smith-Palmer J, Valentine WJ, Cook M, Jethwa M, de Portu S, Pickup JC. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective. Journal of Medical Economics 2016; 19(3): 236-4.

Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics 2016; 19(2): 121-34.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Review of the clinical and economic burden of antibody-mediated rejection in renal transplant recipients. Advances in Therapy 2016; 33(3): 345-56.

Roze S, Smith-Palmer J, Valentine W, Payet V, de Portu S, Papo N, Cucherat M, Hanaire H. Cost-effectiveness of sensor-augmented pump therapy with low glucose suspend versus standard insulin pump therapy in two different patient populations with type 1 diabetes in France. Diabetes Technology & Therapeutics 2016; 18(2): 75-84.

Muduma G, Odeyemi I, Pollock RF. Evaluating the cost-effectiveness of prolonged-release tacrolimus relative to immediate-release tacrolimus in liver transplant patients based on data from routine clinical practice. Drugs Real World Outcomes 2016; 3: 61-8.

Published Manuscripts (2015)

Skovgaard R, Jon Ploug U, Hunt B, Valentine WJ. Evaluating the cost of bringing people with type 2 diabetes mellitus to multiple targets of treatment in Canada. Clinical Therapeutics 2015; 37(8): 1677-88.

Muduma G, Odeyemi I, Pollock RF. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK. Journal of Medical Economics 2015; 18(12): 1050-9.

Muratalina A, Smith-Palmer J, Nurbekova A, Abduakhassova G, Zhubandykova L, Roze S, Karamalis M, Shamshatova G, Demessinov A, Dunne D’Agostino N, Lynch P, Larisa Yedigarova L, Klots M, Valentine W, Welsh J, Kaufman F. Project Baiterek: a patient access program to improve clinical outcomes and quality of life in children with type 1 diabetes in Kazakhstan. Value in Health Regional Issues 2015; 7: 74-9.

Roze S, Smith-Palmer J, Valentine W, de Portu S, Nørgaard K, Pickup JC. Cost-effectiveness of continuous subcutaneous insulin infusion versus multiple daily injections of insulin in type 1 diabetes: a systematic review. Diabetic Medicine 2015; 32(11): 1415-24.

Smith-Palmer J, Boye KS, Perez-Nieves M, Valentine W, Bae JP. Cardiovascular risk profiles in Type 2 diabetes and the impact of geographical setting. Expert Review of Endocrinology & Metabolism 2015; 10: 243–57.

Goh SY, Tan SC, Lim LC, Chua B, Hunt B. Cost-effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp-30) in type 2 diabetes patients with suboptimal glycaemic control in Singapore. Journal of Diabetology 2015; 1:2.

Hunt B, Aguilar Garza JL, Enríquez Vázquez CJ, Jain P, Valentine WJ. Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico. Value in Health Regional Issues 2015; 8c: 20-7.

Valentine WJ, Curtis BH, Pollock RF, Van Brunt K, Paczkowski R, Brändle M, Boye KS, Kendall DM. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Research and Clinical Practice 2015; 109(1): 95-103.

Roze S, Saunders R, Brandt AS, de Portu S, Papo NL, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with type 1 diabetes. Diabetic Medicine 2015; 32(5): 618-26.

Pollock RF, Kappelgaard AM, Seitz L. An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opinion on Drug Delivery 2015; 12(3): 353-60.

Pérez A, Mezquita Raya P, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. Diabetes Therapy 2015; 6(1): 61-74.

Bargalló-Rocha JE, Lara-Medina F, Pérez-Sánchez V, Vázquez-Romo R, Villarreal-Garza C, Martínez-Said H, Shaw-Dulin RJ, Mohar-Betancourt A, Hunt B, Plun-Favreau J, Valentine WJ. Cost-effectiveness of the 21-gene breast cancer assay in Mexico. Advances in Therapy 2015; 32(3): 239-53.

Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infectious Diseases 2015; 15(1): 19.

Published Manuscripts (2014)

Smith-Palmer J, Brändle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Research and Clinical Practice 2014; 105(3): 273-84.

Saunders R, Lian J, Karolicki B, Valentine W. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. Journal of Medical Economics 2014; 17(12): 827-36.

Muduma G, Odeyemi I, Pollock RF. A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. Journal of Medical Economics 2014; 17(7): 520-6.

Giorda CB, Nicolucci A, Pellegrini F, Kristiansen CK, Hunt B, Valentine WJ, Vespasiani G. Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologi-annals initiative: a long-term cost-effectiveness analysis. Diabetic Medicine 2014; 31(5): 615-23.

Muduma G, Odeyemi I, Smith-Palmer J, Pollock RF. Budget impact of switching from an immediate-release to a prolonged-release formulation of tacrolimus in renal transplant recipients in the UK based on differences in adherence. Patient Preference and Adherence 2014; 8: 391-9.

Smith-Palmer J, Kalsekar A, Valentine W. Influence of renal function on long-term graft survival and patient survival in renal transplant recipients. Current Medical Research and Opinion 2014; 30(2): 235-42.

Published Manuscripts (2013)

Ericsson Å, Pollock RF, Hunt B, Valentine WJ. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. Journal of Medical Economics 2013; 16(12): 1442-52.

Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Therapy 2013; 4(2): 417-30.

Lamarsalle L, Hunt B, Schauf M, Szwarcensztein K, Valentine WJ. Evaluating the clinical and economic burden of healthcare-associated infections during hospitalization for surgery in France. Epidemiology and Infection 2013; 141(12): 2473-82.

Rouzier R, Pronzato P, Chéreau E, Carlson J, Hunt B, Valentine WJ. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. Breast Cancer Research and Treatment 2013; 139(3): 621–37.

Pollock RF, Qian Y, Wisniewski T, Seitz L, Kappelgaard AM. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis. Medical Devices: Evidence and Research 2013; 6: 107–14.

Vogel R, Smith-Palmer J, Valentine W. Evaluating the health economic implications and cost-effectiveness of dental implants: a literature review. International Journal of Oral & Maxillofacial Implants 2013; 28(2): 343-56.

Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. Journal of Managed Care Pharmacy 2013; 19(3): 237-46.

Pollock RF, Chilcott J, Muduma G, Valentine WJ. Laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. Journal of Medical Economics 2013; 16(2): 249-59.

Pollock RF, Muduma G, Valentine WJ. Evaluating the cost-effectiveness of laparoscopic adjustable gastric banding versus standard medical management in obese patients with type 2 diabetes in the UK. Diabetes, Obesity and Metabolism 2013; 15(2): 121-9.

Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J. Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. BMC Cancer 2013; 13: 10.

Published Manuscripts (2012)

Pollock RF, Curtis BH, Smith-Palmer J, Valentine WJ. A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in Therapy 2012; 29(12).

Roze S, Kurth H, Hunt B, Valentine W, Marty R. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries. Medical Devices: Evidence and Research 2012; 5: 97-101.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting. Journal of Medical Economics 2012.

Smith-Palmer J, Fajardo-Montañana C, Pollock RF, Ericsson A, Valentine WJ. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden. Journal of Medical Economics 2012; 15(5): 977-86.

Pollock RF, Curtis BH, Valentine WJ. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. Journal of Medical Economics 2012; 15(4): 766-75.

Valentine WJ, Jendle J, Saraheimo M, Thorsteinsson B, Pollock RF, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabetic Medicine 2012; 29(3): 303-12.

Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabetic Medicine 2012; 29(3): 313-20.

Published Manuscripts (2011)

Valentine WJ, Aagren M, Haglund M, Ericsson A, Gschwend MH. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. Scandinavian Journal of Public Health 2011; 39(1): 79-87.

Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents. Clinical Therapeutics 2011; 33(11): 1698-712.

Lippuner K, Pollock RF, Smith-Palmer J, Meury T, Valentine WJ. A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 2011; 9(6): 403-17.

Goodall G, Costi M, Timlin L, Reviriego J, Sacristán JA, Smith-Palmer J, Dilla T. Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus. Endocrinologia y Nutricion 2011; 58(7): 331-340.

Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ. Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. Current Diabetes Reviews 2011; 7(1): 61-74.

Pollock RF, Valentine WJ, Pilgaard T, Nishimura H. The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. Journal of Medical Economics 2011; 14(1): 36-46.

Published Manuscripts (2010)

Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Advances in Therapy 2010; 27(11): 814-27.

Pollock RF, Valentine WJ, Goodall G, Brändle M. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents: A long-term modelling study in Switzerland. Swiss Medical Weekly 2010; 140: w13103.

Smith-Palmer J, Curtis BH, Boye KS, Goodall G, Pillemer SR. Anti-CD3 monoclonal antibody treatment in newly diagnosed type 1 diabetes patients: a hypothetical modelling analysis. Diabetic Medicine 2010; 27(2): 189-96.

Valentine WJ, Pollock RF, Plun-Favreau J, White J. Systematic review of the cost-effectiveness of biphasic insulin aspart 30 in type 2 diabetes. Current Medical Research and Opinion 2010; 26(6): 1399-412.

Published Manuscripts (2009)

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. Diabetes Obesity and Metabolism 2009; 11(11): 1068-79.

Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ. Cost-Effectiveness of Switching to Biphasic Insulin Aspart 30 from Human Insulin in Patients with Poorly Controlled Type 2 Diabetes in South Korea. Value in Health 2009; 12(Suppl 3): S55-S61.

Smith-Palmer J, Kalsekar A, Boye K and Goodall G. The Impact of Obesity on Adverse Cardiovascular Outcomes in the General Population and in Patients with Type 2 Diabetes. Clinical Medicine, Endocrinology and Diabetes 2009; 2: 43-69.

Goodall G, Sarpong EM, Hayes C, Valentine WJ. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocrine Disorders 2009; 5: 9-19.

Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ. An estimation of the long-term clinical and economic benefits of insulin lispro in type 1 diabetes in the UK. Diabetic Medicine 2009; 26(8): 803-14.

Brändle M, Erny-Albrecht KM, Goodall G, Spinas GA, Streit P and Valentine WJ. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. International Journal of Clinical Pharmacology and Therapeutics 2009; 47(8): 501-515.

Gschwend MG, Aagren M, Valentine WJ. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries. Journal of Medical Economics 2009; 12(2): 114-123.

Scherbaum WA, Goodall G, Erny-Albrecht KM, Massi-Benedetti M, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Effectiveness and Resource Allocation 2009; 7(1): 9.

Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Medical Weekly 2009; 139(11-12): 173-84.

Published Manuscripts (2008)

Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: Results and projections from the Steno-2 study. Diabetes Care 2008; 31(8): 1510-5

Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Advances in Therapy 2008; 25(8): 752-74

Valentine WJ, Tucker D, Palmer AJ, Minshall ME, Foos V, Silberman C. Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment: A US Analysis Based on PROactive. Value in Health 2008; 12(1): 1-9

Valentine WJ, Goodall G, Aagren M, Nielsen S, Palmer AJ, Erny-Albrecht K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. Advances in Therapy 2008; 25(6): 567-84

Palmer JL, Goodall G, Nielsen S, Kotchie RW, Valentine WJ, Palmer AJ, Roze S. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study. Current Medical Research and Opinion 2008; 24(5): 1417-28

Ray JA, Borker R, Barber B, Valentine WJ, Belozeroff V, Palmer AJ. Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA. Value in Health 2008; 11(5): 800-8

Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Valentine WJ, Palmer AJ. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value in Health 2008; 11(S1): S43-51

Goodall G, Jendle JH, Valentine WJ, Munro V, Brandt AB, Ray JA, Roze S, Foos V, Palmer AJ. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. International Journal of Clinical Practice 2008; 62(6): 869-76

Minshall ME, Oglesby AK, Wintle ME, Valentine WJ, Roze S, Palmer AJ. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value in Health 2008; 11(1): 22-33

Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrology Dialysis Transplantation 2008; 23(4): 1216-23

Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia. J Med Econ 2008; 11(4): 651-670.

Published Manuscripts (2007)

Valentine WJ, Bottomley JM, Palmer AJ, Brandle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabetic Medicine 2007; 24(9): 982-1002

Cohen N, Minshall ME, Sharon-Nash L, Zakrzewska K, Valentine WJ, Palmer AJ. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007; 25(10): 881-97

Gilmer TP, Roze S, Valentine WJ, Emy-Albrecht K, Ray JA, Cobden D, Nicklasson L, Philis-Tsimikas A, Palmer AJ. Cost-effectiveness of diabetes case management for low-income populations. Health Services Research 2007; 42(5): 1943-59

Palmer AJ, Valentine WJ, Ray JA. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. International Journal of Clinical Practice 2007; 61(10): 1626-33

Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Current Medical Research and Opinion 2007; 23(3): 609-22

Valentine WJ, Erny-Albrecht KM, Ray JA, Roze S, Cobden D, Palmer AJ. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. Advances in Therapy 2007; 24(2): 273-90

Palmer AJ, Valentine WJ, Ray JA, Roze S, Muszbek N. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. European Journal of Health Economics 2007; 8(2): 161-68

Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. Diabetes, Obesity and Metabolism 2007; 9(1): 103-13

Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I, Lammert M, Roze S. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. Current Medical Research and Opinion 2007; 23(4): 895-901

Published Manuscripts (2006)

Valentine WJ, Palmer AJ, Nicklasson L, Cobden D, Roze S. Improving life expectancy and decreasing the incidence of complications associated with type 2 diabetes: a modelling study of HbA1c targets. International Journal of Clinical Practice 2006; 60(9): 1138-45

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de ZD, Parving HH, Laville M. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Current Medical Research and Opinion 2006; 22(11): 2095-100

Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brandle M. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland. Swiss Medical Weekly 2006; 136(21): 346-52

Tucker DM, Palmer AJ, Valentine WJ, Roze S, Ray JA. Counting the costs of overweight and obesity: modeling clinical and cost outcomes. Current Medical Research and Opinion 2006; 22(3): 346-52

Valentine WJ, Palmer AJ, Erny-Albrecht KM, Ray JA, Cobden D, Foos V, Lurati FM, Roze S. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Advances in Therapy 2006; 23(2): 191-207

Roze S, Valentine WJ, Evers T, Palmer AJ. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting. Current Medical Research and Opinion 2006; 22(7): 1415-24

Palmer AJ, Chen R, Valentine WJ, Roze S, Bregman B, Mehin N, Gabriel S. Cost-consequence analysis in a French setting of screening and optimal treatment of nephropathy in hypertensive patients with type 2 diabetes. Diabetes and Metabolism 2006; 32(1): 69-76

Palmer AJ, Roze S, Rodby RA, Valentine WJ, Ritz E, Lehnert H. Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy. Deutsche Medizinische Wochenschrift 2006; 131(31): 1721-6

Published Manuscripts (2005)

Valentine WJ, Palmer AJ, Lammert M, Nicklasson L, Foos V, Roze S. Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin naive type 2 diabetes patients: cost-effectiveness analysis in the UK setting. Current Medical Research and Opinion 2005; 21(12): 2063-71

Roze S, Valentine WJ, Zakrzewska KE, Palmer AJ. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabetic Medicine 2005; 22(9): 1239-45

Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, Davey P, Palmer AJ. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Current Medical Research and Opinion 2005; 21(10): 1617-29

Minshall ME, Roze S, Palmer AJ, Valentine WJ, Foos V, Ray J, Graham C. Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. Clinical Therapeutics 2005; 27(6): 940-50

Palmer AJ, Tucker DM, Valentine WJ, Roze S, Gabriel S, Cordonnier DJ. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies. Nephrology Dialysis Transplantation 2005; 20(6): 1103-9

Palmer AJ, Valentine WJ, Roze S, Lammert M, Spiesser J, Gabriel S. Overview of costs of stroke from published, incidence-based studies spanning 16 industrialized countries. Current Medical Research and Opinion 2005; 21(1): 19-26

Published Manuscripts (2004)

Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Current Medical Research and Opinion 2004; 20(11): 1729-46

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Current Medical Research and Opinion 2004; 20(S1): S5-26

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Lammert M, Spinas GA. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Current Medical Research and Opinion 2004; 20(S1): S27-40

Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Current Medical Research and Opinion 2004; 20(S1): S41-51

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Hayes C, Oglesby A, Spinas GA. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Current Medical Research and Opinion 2004; 20(S1): S52-58

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model. Current Medical Research and Opinion 2004; 20(S1): S59-66

Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy. Current Medical Research and Opinion 2004; 20(S1): S67-73

Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical Therapeutics 2004; 26(2): 304-21

Close phone HUD
+41 61 271 6214
Dial with SkypeOutDial with SkypeOut
Close phone HUD
+41 79 340 4644
Dial with SkypeOutDial with SkypeOut